COMP <GO>
MBX vs VCRE // EV/EBITDA & P/E VALUATION
MBX Biosciences Inc. (NASDAQ) VS. Vicore Pharma Holding AB (NASDAQ) • 15-METRIC TALLY: MBX 1
— VCRE 1
■ METRIC PARITY
LAST: $54.54 (+0.70%) • MKT CAP: $2.63B
valuation
—
LAST: $10.20 (+4.56%) • MKT CAP: $2.87B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MBX VS. VCRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MBX | VCRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -26.40% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.12% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 51.9 | +1.92 | MBX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $2.87B | -$244.9M | VCRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MBX REV | VCRE REV | MBX GROSS % | VCRE GROSS % | MBX FCF | VCRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$81.9M | — |
| FY 2024 | $0 | — | — | — | -$55.6M | — |
| FY 2023 | $0 | — | — | — | -$32.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MBX // BETA —
VCRE // BETA —